Kolon Life Science succeeds in exporting ‘Invossa’ technology for KRW 500 billion
Kolon Life Science(CEO Woo-Seok Lee) will export technology of the world’s first cell and gene therapy for degenerative arthritis, ‘Invossa,’ to Japan. This is the result of Invossa’s safety and efficacy recognized in the international market in the progress of the final examination for its produ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
